[1] Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer′s disease. Brain, 2008, 131(Pt 6): 1630-1645.
[2] Fodero-Tavoletti MT, Smith DP, McLean CA, et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci, 2007, 27(39): 10365-10371.  doi: 10.1523/JNEUROSCI.0630-07.2007
[3] Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer′s disease with Pittsburgh Compound-B. Ann Neurol, 2004, 55(3): 306-319.  doi: 10.1002/ana.20009
[4] Jack CR Jr, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011, 7(3): 257-262.  doi: 10.1016/j.jalz.2011.03.004
[5] Raji CA, Becker JT, Tsopelas ND, et al. Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer′s disease with Pittsburgh Compound B. J Neurosci Methods, 2008, 172(2): 277-282.
[6] Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer′s disease. Brain, 2008, 131(Pt6): 1630-1645.
[7] Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol, 2009, 21(1): 117-128.
[8] Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging, 2011, 32 Suppl 1: S20-36.
[9] Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci, 2007, 27(23): 6174-6184.  doi: 10.1523/JNEUROSCI.0730-07.2007
[10] Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med, 2004, 256(3): 183-194.
[11] 程怀东, 汪凯.遗忘型轻度认知损害的早期诊断途径:从分子、影像到行为神经病学.中国现代神经疾病杂志, 2010, 10(2): 155-159.  doi: 10.3969/j.issn.1672-6731.2010.02.003
[12] Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 2007, 130(Pt11): 2837-2844.
[13] Jack CR Jr, Wiste HJ, Vemuri P, et al. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain, 2010, 133(11): 3336-3348.  doi: 10.1093/brain/awq277
[14] Savva GM, Wharton SB, Ince PG, et al. Age, neuropathology, and dementia. N Engl J Med, 2009, 360(22): 2302-2309.  doi: 10.1056/NEJMoa0806142
[15] Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C-PiB and structural MRI provide complementary information in imaging of Alzheimer′s disease and amnestic mild cognitive impairment. Brain, 2008, 131(Pt3): 665-680.
[16] Jacobs B, Schall M, Prather M, et al. Regional dendritic and spine variation in human cerebral cortex: a quantitative golgi study. Cereb Cortex, 2001, 11(6): 558-571.  doi: 10.1093/cercor/11.6.558
[17] Attems J, Thal DR, Jellinger KA. The relationship between subcortical tau pathology and Alzheimer's disease. Biochem Soc Trans, 2012, 40(4): 711-715.
[18] Tosun D, Schuff N, Mathis CA, et al. Spatial patterns of brain amyloid-beta burden and atrophy rate associations in mild cognitive impairment. Brain, 2011, 134(Pt4): 1077-1088.
[19] Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol, 2008, 65(11): 1509-1517.  doi: 10.1001/archneur.65.11.1509
[20] Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol, 2010, 67(1): 122-131.  doi: 10.1002/ana.21843
[21] Price JL, Davis PB, Morris JC, et al. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. Neurobiol Aging, 1991, 12(4): 295-312.  doi: 10.1016/0197-4580(91)90006-6
[22] Vlassenko AG, Benzinger TL, Morris JC. PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta, 2012, 1822(3): 370-379.  doi: 10.1016/j.bbadis.2011.11.005
[23] Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 2011, 7(3): 280-292.  doi: 10.1016/j.jalz.2011.03.003
[24] Sheline YI, Raichle ME, Snyder AZ, et al. Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry, 2010, 67(6): 584-587.  doi: 10.1016/j.biopsych.2009.08.024
[25] Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol, 2010, 9(4): 363-372.  doi: 10.1016/S1474-4422(10)70043-0
[26] Alexander D, Robert P. Imaging amyloid in the human brain: a promising tool for improved early diagnosis and treatment monitoring in Alzheimer′s Disease. Open Nucl Med J, 2010, 2: 53-57.